Dicerna Pharmaceuticals (DRNA) Earns Daily Media Impact Score of 0.06

News stories about Dicerna Pharmaceuticals (NASDAQ:DRNA) have been trending somewhat positive on Thursday, according to Accern. Accern scores the sentiment of news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Dicerna Pharmaceuticals earned a media sentiment score of 0.06 on Accern’s scale. Accern also gave news headlines about the biopharmaceutical company an impact score of 45.8073800129943 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.

Here are some of the news headlines that may have effected Accern Sentiment Analysis’s analysis:

Dicerna Pharmaceuticals (NASDAQ DRNA) traded up $0.34 during trading on Thursday, reaching $7.84. 177,200 shares of the company were exchanged, compared to its average volume of 176,034. Dicerna Pharmaceuticals has a fifty-two week low of $2.42 and a fifty-two week high of $10.24.

Dicerna Pharmaceuticals (NASDAQ:DRNA) last released its quarterly earnings data on Thursday, November 2nd. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.70) by ($0.22). The business had revenue of $0.47 million during the quarter. Dicerna Pharmaceuticals had a negative net margin of 5,895.26% and a negative return on equity of 293.25%. The company’s quarterly revenue was up 192.6% compared to the same quarter last year. During the same period last year, the company earned ($0.68) EPS. equities analysts predict that Dicerna Pharmaceuticals will post -3.04 earnings per share for the current fiscal year.

DRNA has been the subject of a number of recent research reports. Zacks Investment Research lowered shares of Dicerna Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Tuesday, August 22nd. ValuEngine upgraded shares of Dicerna Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Thursday, November 2nd. Finally, HC Wainwright reiterated a “buy” rating and issued a $10.00 price objective (up from $6.00) on shares of Dicerna Pharmaceuticals in a research note on Friday, November 3rd. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $6.81.

COPYRIGHT VIOLATION WARNING: This piece was originally posted by Ticker Report and is the property of of Ticker Report. If you are viewing this piece on another domain, it was illegally copied and republished in violation of United States & international trademark & copyright legislation. The correct version of this piece can be accessed at https://www.tickerreport.com/banking-finance/3094754/dicerna-pharmaceuticals-drna-earns-daily-media-impact-score-of-0-06.html.

About Dicerna Pharmaceuticals

Dicerna Pharmaceuticals, Inc is a ribonucleic acid (RNA) interference-based biopharmaceutical company. The Company operates in the segment of discovery, research and development of treatments based on its RNA interference (RNAi) technology platform. The Company is focused on the discovery and development of treatments for rare inherited diseases involving the liver and for cancers that are genetically defined.

Insider Buying and Selling by Quarter for Dicerna Pharmaceuticals (NASDAQ:DRNA)

Receive News & Ratings for Dicerna Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dicerna Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.